Neuphoria Therapeutics Inc. (NEUP) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.05 (-0.33% 1D, market cap $16.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NEUP ranks #774 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NEUP carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.8%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and AEON (AEON Biopharma Inc. (Class A)) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M). Among the 5-stock peer group, NEUP leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
Per NEUP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001191070), Neuphoria Therapeutics Inc. generated $15.6M in revenue (-68.8% YoY), -$369.6K in net income, and $77.2K in free cash flow against $36.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($77.2K FCF) & 52% Gross Margin
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While NEUP currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.54) and Max Pain ($3.20) forces dealer call-delta covering toward $5.81.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Neuphoria Therapeutics Inc. (NEUP) slipped -0.33% to $3.05, trading at 2% of its 52-week range ($3.03 – $5.53). Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NEUP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NEUP. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuphoria Therapeutics Inc. (NEUP) ranks #774 by composite RQD confidence (31/100, grade E) and #843 by equity capitalization ($16.5M). Within this direct 5-issuer industry benchmark cohort, NEUP leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. AEON currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NEUP at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NEUP
ACTIVE
Neuphoria Therapeutics Inc. | E | 31/100 | — | — | -11.8% | -0.33% | $16.5M | Benchmark Subject |
| MRKR Marker Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -2.97% | $16.3M | /mrkr-vs-neup → |
| AEON AEON Biopharma Inc. (Class A) | D | 46/100 | — | — | -35.0% | -6.80% | $16.2M | /aeon-vs-neup → |
| RADX Radiopharm Theranostics Limited | D | 46/100 | — | — | — | -3.26% | $15.6M | /radx-vs-neup → |
| PBM Psyence Biomedical Ltd. | D | 46/100 | — | — | — | -8.31% | $17.6M | /pbm-vs-neup → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Neuphoria Therapeutics Inc. (NEUP) reported GAAP revenue of $15.6M (-68.8% vs. FY2024 revenue of $50.1M , and -74.6% cumulative change since FY2023) , GAAP net income of -$369.6K, operating cash flow of $77.2K, and free cash flow of $77.2K (+100.5% YoY). On the balance sheet, NEUP closed FY2025 with $36.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $15.6M | -$369.6K | $77.2K | $77.2K | $36.6M | — |
| FY2024 (FY) | 2024-06-30 | $50.1M | -$15.5M | -$14.7M | -$14.7M | $18.2M | — |
| FY2023 (FY) | 2023-06-30 | $61.6M | -$21.4M | -$14.6M | -$14.6M | — | — |
As of 2026-11-03, Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.05 (-0.33% 1D, market cap $16.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NEUP ranks #774 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NEUP carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.8%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and AEON (AEON Biopharma Inc. (Class A)) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M). Among the 5-stock peer group, NEUP leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
Per NEUP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001191070), Neuphoria Therapeutics Inc. generated $15.6M in revenue (-68.8% YoY), -$369.6K in net income, and $77.2K in free cash flow against $36.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NEUP last traded at $3.05 (-0.33% on volume of 70,253 shares), positioning the stock -13.84% below its 50-day simple moving average ($3.54) and -26.51% below its 200-day simple moving average ($4.15). Across its 52-week range of $3.03 to $5.53, NEUP sits at the 0.8% percentile with a 14-day RSI of 26.1 (OVERSOLD (<32)) and an implied next-earnings move of ±8.3% ($2.80 to $3.30).
Per the Roarable RQD rating, NEUP carries an RQD Score of 31 and a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The score is the sum of five pillars, each scored out of 20:
For a prospective investor evaluating the stock today, the rating points to weak fundamentals, weak institutional and insider support signals, and a fragile balance sheet. Upside drivers would have to come from a change in the underlying cash-generation profile, which the reported figures do not yet show. The rating does not establish a price target or a specific timeline, and it should be weighed against the fact that several inputs (valuation multiples, analyst coverage, holder data) are unavailable in the source data.
Neuphoria Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations.
Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are therefore — The only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations and a beta of 1.0. No 2nd-order bottlenecks can be identified from the source data.
Analyst data: —
Holders (SEC Form 4, 13F, Congressional PTR): —
Real-time company headlines, analyst actions, and sector developments for Neuphoria Therapeutics Inc. (NEUP) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.
Long NEUP at $3.05 targeting $3.66. FY 2025 revenue of $15.6M and positive FCF of $0.1M, with cash rising to $22.2M, mark a clear improvement from the FY 2024 net loss of $-15.5M.. Institutional whale score is 3/20 and the risk/reward vs. the $3.03 52-week low is skewed heavily in favor of bulls.
Both sides have a point here — NEUP's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Sitting on the sidelines or leaning short NEUP above $3.05. An RQD score of 31 (grade E) with an Altman Z-Score of 0.2 and ROIC of -11.8% signals forensic balance-sheet and cash-generation risk.. Until Fundamental Cash Engine (8/20) and FCF yield (0.47%) inflect higher, upside is capped near $5.53.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).